Updated on 3 September 2013
In the case of the regulatory issues raised against the company's Chikalthana facility in August, he said that the observations raised were not as serious as Waluj. The Chikalthana facility had received ‘483' observations after the US FDA and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had conducted inspections there.
The managing director of the company plans to now meet officials from the UK MHRA and US FDA to personally explain this to them.
The company is further considering shifting its products to the nearby Shendra facility that received MHRA clearance. The chairman said that the US regulatory body, FDA will be visiting the manufacturing unit next month for an inspection.